PD-L1 Expression on Circulating Tumour-Derived Microvesicles as a Complementary Tool for Stratification of High-Grade Serous Ovarian Cancer Patients.
PD-L1
biomarkers
flow cytometry
immunohistochemistry
microvesicles
ovarian cancer
precision medicine
translational research
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Oct 2021
16 Oct 2021
Historique:
received:
23
09
2021
revised:
13
10
2021
accepted:
14
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
Ovarian cancer (OC) has recently attracted attention for the use of PD-1/PD-L1 axis blocking agents, with durable activity reported only in a subset of patients. The most used biomarker for sensitivity to the PD-1/PD-L1 axis blockade is tumour PD-L1 status by immunohistochemistry. However, patient stratification using this method suffers from intrinsic heterogeneity of OC, likely contributing to the unsatisfactory results obtained so far. Cells communicate with each other by releasing microvesicles (MVs) that carry parental cell surface features. Thus, we hypothesised that PD-L1 We showed for the first time the presence of measurable amounts of TC- and leukocyte-derived PD-L1 The enumeration of circulating PD-L1
Sections du résumé
BACKGROUND
BACKGROUND
Ovarian cancer (OC) has recently attracted attention for the use of PD-1/PD-L1 axis blocking agents, with durable activity reported only in a subset of patients. The most used biomarker for sensitivity to the PD-1/PD-L1 axis blockade is tumour PD-L1 status by immunohistochemistry. However, patient stratification using this method suffers from intrinsic heterogeneity of OC, likely contributing to the unsatisfactory results obtained so far. Cells communicate with each other by releasing microvesicles (MVs) that carry parental cell surface features. Thus, we hypothesised that PD-L1
RESULTS
RESULTS
We showed for the first time the presence of measurable amounts of TC- and leukocyte-derived PD-L1
CONCLUSIONS
CONCLUSIONS
The enumeration of circulating PD-L1
Identifiants
pubmed: 34680346
pii: cancers13205200
doi: 10.3390/cancers13205200
pmc: PMC8534085
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Roche SpA
ID : ML41134
Références
Sci Rep. 2020 Nov 9;10(1):19296
pubmed: 33168847
Sci Rep. 2017 Mar 07;7:42929
pubmed: 28266500
JAMA Oncol. 2019 Aug 1;5(8):1141-1149
pubmed: 31194228
JAMA Oncol. 2019 Mar 1;5(3):393-401
pubmed: 30676622
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Cancer Res. 2004 Oct 1;64(19):7045-9
pubmed: 15466198
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Cancer Biomark. 2013;13(5):351-7
pubmed: 24440975
Ann Oncol. 2019 May 1;30(5):672-705
pubmed: 31046081
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Int J Mol Sci. 2020 Jul 28;21(15):
pubmed: 32731639
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
Cancer. 2020 Nov 15;126(22):4867-4877
pubmed: 32914866
Signal Transduct Target Ther. 2020 Jul 29;5(1):137
pubmed: 32728057
Sci Rep. 2021 Mar 18;11(1):6400
pubmed: 33737722
Arch Med Res. 2013 Apr;44(3):208-14
pubmed: 23506723
Int Immunopharmacol. 2017 Nov;52:7-14
pubmed: 28846888
Carcinogenesis. 2014 Sep;35(9):2113-20
pubmed: 24925027
Oncotarget. 2016 Jan 12;7(2):1486-99
pubmed: 26625204
J Transl Med. 2019 Oct 29;17(1):355
pubmed: 31665020
Trends Cell Biol. 2009 Feb;19(2):43-51
pubmed: 19144520
Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188395
pubmed: 32698041
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
Int J Gynecol Cancer. 2020 Jul;30(7):1034-1042
pubmed: 32527769
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
Ther Adv Med Oncol. 2014 Sep;6(5):229-39
pubmed: 25342990
J Extracell Vesicles. 2013 Sep 12;2:
pubmed: 24223256
Expert Opin Emerg Drugs. 2020 Dec;25(4):445-453
pubmed: 33040627
J Extracell Vesicles. 2018 Mar 22;7(1):1454776
pubmed: 29696076
Br J Cancer. 2018 Mar 20;118(6):820-824
pubmed: 29509748
Int J Mol Sci. 2020 Aug 29;21(17):
pubmed: 32872424
J Clin Oncol. 2021 Jun 10;39(17):1842-1855
pubmed: 33891472
Transl Oncol. 2016 Feb;9(1):64-69
pubmed: 26947883
EBioMedicine. 2021 Jan;63:103137
pubmed: 33310681
Int J Gynaecol Obstet. 2014 Jan;124(1):1-5
pubmed: 24219974
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Lung Cancer. 2020 Sep;147:91-98
pubmed: 32683207
Ann Oncol. 2020 Sep;31(9):1148-1159
pubmed: 32569725
Cancer Treat Rev. 2020 Dec;91:102111
pubmed: 33068886
Biomed Res Int. 2013;2013:703048
pubmed: 23484144
Oncotarget. 2018 Jun 8;9(44):27460-27470
pubmed: 29937998
Gynecol Oncol. 2020 Mar;156(3):523-529
pubmed: 31916979
BMJ. 2020 Nov 9;371:m3773
pubmed: 33168565
Sci Rep. 2021 Feb 12;11(1):3750
pubmed: 33580098
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
Leukemia. 2006 Sep;20(9):1487-95
pubmed: 16791265
Int J Mol Sci. 2019 Apr 18;20(8):
pubmed: 31003463
Ann Oncol. 2018 Jan 1;29(1):193-199
pubmed: 29361135
J Cell Biochem. 2019 Apr;120(4):6361-6369
pubmed: 30304550
Platelets. 2017 May;28(3):256-262
pubmed: 28277059
Cancer Immunol Res. 2018 Feb;6(2):236-247
pubmed: 29301753
Nat Immunol. 2021 May;22(5):560-570
pubmed: 33753940